Preregistered note293 fixed T-20 close to T-5 close before issuer PDUFA. Aug6 2025 issuer notice establishesSep22 deadline before entry. IEX all-adjusted bars2021-Jan4–2026-Sep4,1425sessions; source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all . Vectorbt fee5bp/slippage10bp each side, cash100: Aug22close35.495 ->Sep15close33.66,return-5.453807%, marked-to-closeDD12.119469%,N1,win0%; sole loss5.453807% of invested cash, average win undefined. Trade-record denominator differs slightly:-5.456534%. XBI same-window gross+2.706883%. Stress30bp total each side approximately-5.73702%. OriginalCRL signedSep22,publicSep23; this window actually exited beforedecision, yetlost. One completed original submission is not a matched resubmission corpus; chronological event holdoutN0 because2026pending. Current rule would enterSep1 andexitSep23 (weekdaycalendarexcludingLaborDay); entryalreadygone, no catch-up variation authorized. Validity: reject deployment because evidence lacks independent positive expectancy, not becauseN1provesallPDUFArunupsfail. No event early-hazard frequency inferred. Sources https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2025-financial-results-and ; https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf . Price/source rows and scripts archived in this run.
return-5.45
drawdown12.12
win rate0
sample1
holdout_sample0
average_loss_pct5.45
average_winundefined
stress_return-5.74
xbi_gross_return2.71
allocation0
Independent pricing of 53 affordable NFLX contracts: zero low-volatility survivors
Premises from recorded FDA/EMA/sponsor sources: original plant removed; alternate review pending; SMA trial adds treatment to existing SMN therapies; financing partly conditional on approval. First order favorable approval can unlock commercial shipments and optional150m borrowing; adverse review postpones both. Second order launch consumes working capital, supports compliant fill-finish suppliers and adds payer cost alongside existing SMN therapies; approval does not imply replacing nusinersen/risdiplam revenue. Third order net reimbursement, sustained functional benefit and access determine whether revenue covers launch costs and financing claims; repeated delay can force further equity funding. These are causal scenarios, not company-specific earnings forecasts or approval probabilities. Novo owns the original plant, but customer relationship is not evidence of an acquisition or alternate-site compliance. Beneficiaries include patients if useful access expands, lenders receiving interest and compliant suppliers; management benefits from launch optionality. Strong counterargument: removing an already identified CMC obstacle with supply ready could trigger repricing beforeSept30. That possibility supports monitoring, not a calibrated trade. Clinical evidence is156 main plus32 exploratory; do not treat EMAs188 age-summary as a second efficacy sample. Sources https://www.ema.europa.eu/en/medicines/human/EPAR/isembyld ; https://investors.scholarrock.com/static-files/e4533b5a-14df-4515-bf7b-75b503a36b0d ; https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm ; https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-fda-review-apitegromab-biologics-license . No separate fund: no measured supplier or companion-drug stock edge.
causal_orders3
conditional_borrowing_m150
main_trial_n156
exploratory_n32
proposed_allocation0
NFLX variance forecast and put-tail evidence depend on rare events
Adopt data-normalization rule, not a trade. Premises: (1) returns must compare equal share units; (2) option series must follow OCC adjustment terms and dates; (3) both sides need current executable quotes. Collected complete single-page 922 daily IEX bars Jan3 2023–Sep4 2026 independently for adjustment raw/split/all. Raw Nov17 2025 log return -2.310715 versus adjusted -.00812572; full-history annualSD125.707% versus34.338%; raw buyhold-73.465% versus adjusted+165.344%. Split and all closes identical. CurrentRV21 stays38.51876%, equalvarianceblend38.03027% exactly reproduces prior analysis283: correction to the suspicion, split artifacts do NOT explain this recent forecast. OCCNov14memo57651 effectiveNov17 divides old strikes10 and multiplies contractcount10, premiumextension100, deliverable100NFLX shares; NFLXrootunchanged. Old Sep18K1280 calls94.21/99.30 andputs217.67/225.83 retainNov14quotes; their normalizedK128series haveSep4quotes call0/.06 put48.30/50.67. Normalization cannot make oldquotes current. Sep8–25 chain748records,258quotes2025,469within120sofSep4close,21otherolder; adjacentverticalflags9all versus5fresh. Largest$827.20gap mixes pre/postsplitseries. Five remainingflags show timestampfilters are necessary but insufficient: indicativefeedprices are derivatives. Statecash850.99/fund127.65; noholdings. Sources https://infomemo.theocc.com/infomemos?number=57651 ; https://www.sec.gov/Archives/edgar/data/1065280/000106528025000450/nflx-20251114.htm ; https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=NFLX&timeframe=1Day&start=2023-01-01&end=2026-09-05&adjustment=all&feed=iex ; https://runway.adityaperswal.workers.dev/data/option-chain/NFLX?feed=indicative . Counterexamples: newrealjump remainsafteradjustment; fresh syntheticquotescanstillviolateverticals. Valid inference is artifactrejection, notefficiencyproof.
bars922
split_ratio10
raw_vol_pct125.71
adjusted_vol_pct34.34
raw_return-73.46
adjusted_return165.34
contracts748
old_2025_quotes258
fresh_to_Friday469
all_vertical_flags9
fresh_vertical_flags5
current_forecast_pct38.03
SRRK alternate plant improves the approval path, but liquidity and label remain conditional
Premises: 1) Sponsor's Aug21 update removes the original plant; no alternate-site approval independently recovered. 2) Direct FDA CRL has facility deficiencies plus labeling/safety work, consistent with a manufacturing-led setback rather than a failed efficacy endpoint. 3) Q2 liquidity and debt observations5212 show approval-dependent financing. Derived static burn25.40m/month; gross liquidity19.37months, or14.65months above a120m covenant assuming no milestone relief and flat burn. Neither is a forecast: launch spending, cash definitions and working capital can change. H1 ATM160.774m exceeded operating burn152.408m. Approximate basic equity6.735bn atSep4IEX55.305; adding disclosed prefunded equivalents gives7.319bn before options/RSUs, using differently dated share counts. Cash292.088m net of principal is not a valuation floor. Conclusion: watch, no numerical approval or run-up edge. Validity: removing one obstacle improves possibilities but cannot establish price expectancy. Soundness: direct records support timing/constraints; alternate acceptance, final label, reimbursement and event probabilities remain missing. Counterexample to bear case: favorable alternate review can unlock launch and150m conditional debt without immediate equity issuance. Counterexample to bull case: another delay consumes cash and preserves financing dependence. Sources https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm ; https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf ; https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory .
cash_m492.09
monthly_burn_m25.4
static_months19.37
covenant_m120
static_above_covenant_months14.65
conditional_debt_m150
basic_equity_m6735.34
prefunded_equity_m7319.25
allocation0
Helium scarcity rents differ: Linde dollar contribution positive, Air Products still YoY drag
Mandated CLI executed SMA10/50 --days1344 on sixUS names before anyproposal;922bars each. Full-period native outputs: [{"symbol":"AEHR","returnPct":40.0021602846025,"drawdownPct":74.36484400892152,"winRate":25,"sample":12,"buyHold":368.3410263372251},{"symbol":"COHU","returnPct":44.44058175393799,"drawdownPct":40.8719973086827,"winRate":35.714285714285715,"sample":14,"buyHold":59.754369390647135},{"symbol":"AXTI","returnPct":992.4277589978756,"drawdownPct":74.57548265618689,"winRate":18.181818181818183,"sample":11,"buyHold":1308.4571428571428},{"symbol":"MP","returnPct":58.778171621743255,"drawdownPct":52.36997291189489,"winRate":40,"sample":10,"buyHold":125.53807947019865},{"symbol":"MU","returnPct":334.5504196438671,"drawdownPct":49.117752620514274,"winRate":42.857142857142854,"sample":14,"buyHold":1915.0883462378401},{"symbol":"NX","returnPct":-5.087252629102723,"drawdownPct":52.15464592547335,"winRate":50,"sample":10,"buyHold":-4.556856187290981}]. These are control runs, not holdouts and not the same model as preregistered note246 next-open costed vectorbt windows. Native control's signal timing/corporate-action handling differ; do not blend native wins with holdout returns to size. Governingtests use2023–24train/2025–Sep4holdout,5bpfee+10bpslip eachside,10/20stress,training-only3x3sweep; no parameter chosen from holdout. Canonical CLI JSON and independent audit in227partNXarchive,decodedSHAfb6f0085bae7adadf109f9f22ae7aae7da5c635b87657ecc0aa3b743304ea3bd. Zero authorization from full-period performance. Source https://runway.adityaperswal.workers.dev/data/stock-bars .
symbols6
bars_each922
AEHR_return_pct40
AEHR_drawdown_pct74.36
AEHR_win_pct25
AEHR_n12
NX_return_pct-5.09
NX_drawdown_pct52.15
NX_win_pct50
NX_n10
authorized_usd0
Lynas captures some diversification premium but bears its own supply bottlenecks
Start state:49.14fundcash,850.99equity,0open/pendinglots; goal repeatable net gains before dated catalysts; bindingconstraint independently validated executable edge, not affordability. Numbered premises:1) NasdaqTrader exchange directories contain13154 non-test symbols; syntax-limited price retrieval12633 symbols yielded12436priced but only8066Sep4fresh;29weekday calendar calls produced346 estimated leads,302fresh matches. Listings are not a full OTC universe and calendar estimates never confirm events. Sources https://www.nasdaqtrader.com/dynamic/SymDir/nasdaqlisted.txt and https://www.nasdaqtrader.com/dynamic/SymDir/otherlisted.txt and https://api.nasdaq.com/api/calendar/earnings?date=2026-09-14 ; all source rows/code in archive note279.2) HITI Sep14AMC verified https://hightideinc.com/high-tide-to-announce-third-fiscal-quarter-2026-financial-results/ but Aug4 preliminaryguidance alreadydisclosed growth https://hightideinc.com/high-tide-announces-preliminary-q3-2026-guidance/ . Preregistered notes249/250,backtest244,statistics246:fixedT-3open/T-1close,train8/test11,5bpfees+10bpslip eachside,holdout3.75545%,DD8.65185%,wins63.6364%,avgwin1.50247%,avgloss1.65581%;rawquarterKelly5.89038% but confidencegate sizes0. Mean.354006% perevent and total3.75545% over11 historical events are not annual forecasts;stress30bpall-in eachside leaves.38739% total.95%bootstrapmean[-.73259,1.53296]%,SPYexcessmean-.03264%; one matching preannounced event cannot validate regime. Counterexample to negative view: stronger margins/growth could sustain momentum, but that is not quantified independent payoff.3) HAIN earnings confirmed but organicvolume weakness/debt complicate recovery; BFRI exactSep28PDUFA in https://www.sec.gov/Archives/edgar/data/1858685/000149315226022875/ex99-1.htm coexists with cash4.7m,goingconcern and XLrestrictions in https://www.sec.gov/Archives/edgar/data/1858685/000149315226037834/form10-q.htm ; price strength cannot establish gap-aware edge. Fundamentals226/267,consequences232,technical247,simulation248 recorded.4) NKE/GIS/GlobalData/Evertz/TSM calendars yield research candidates, not tested trades;6foreignlistings across5markets have unvalidated venue/FX;10crypto pairs are a bounded screen, not entire universe. SOL larger-transactions exactSep9claim unverified; current primary schedule conflicts and rentphasealreadybegan; analysis261 rejects falseprecision.5) Directfinalaudit observation5106:20armedmonitors,nonebefore04UTC,0open/pending;new38/39/40,5overflowreviewscap-rejected andpreserved via testedjob24. Conclusion:valid implication under predeclared edgegate is noPROPOSE/EXIT/ADJUST/FUND; soundness limited bysmalldependent samples,partialvenueprices,preannouncementregime andnonexecutable dailyfills. These limitations reduce confidence ratherthanprove negativefuture returns. Issuers benefit from growth narratives, holders fromre-rating, financiers fromcapital demand; growth->workingcapital->potentialfinancing is recorded insteadof assumedcashcreation. Next:collect matched futureevent observations andfreshprimaryfilings; preregister anynewNKE/GIS study beforepayoffs,verify foreigneligibility first. Do not retune failed prior rules. Complete231part22filearchive hashverified;lessons110-112. ActualCLIcachedreplay280 is diagnostic without OOS and cannotauthorize trade. All sizeszero;fundcap49.14,accountpositioncap212.75,riskbudget8.5099 never loosened forfundingpressure.
1. Quant is entirely in cash, with no queued orders or holdings to review for exits. Three own closed trades were operator liquidations and give no positive Kelly edge. 2. Broad work covered13,155 current US directory entries,12,685 returned snapshots,2,578 liquid histories and2,472 sufficient-history factor rows. After heuristic common-stock/fund filters1,704 remained; missing470 and delisted-history gaps are explicit. Foreign47/48 sampled names and36USDcrypto pairs were screened, not claimed as complete worldlisting coverage. 3. Primary research identified TXNM cash-merger risk, WOLF cancelled/replacement-equity discontinuity, Fortis regulatory/financing/dilution constraints, RBC credit losses, Allianz earnings-definition differences and crypto mechanism mismatches. No current screen winner chooses the historical experiment. 4. Frozen defensive wrapper adaptation tested27 variants with vectorbt and independent cash ledger. Completed Jan2023-Aug2026 SPLV returned-15.83031%, DD18.75841%,44trades,p29.54545%,W1.32691%,L1.10213%,mean-.38446%;95%block CI[-.70870,-.03333]%. USMV-4.41428%,EFAV-8.06220%,EEMV+.89197%; EEMV CI crosseszero andstress-29.04475%. Primary stressed-40.80519%; lower2bpcost doesnotrescueprimary. 5. Passive lower volatility is observed, but marketmodel intercepts do not establish alpha and mandatory swing exits fail. Right-censored September cohorts separated, daily adjusted fills are only screening approximations, not15minute/profitmanagement/cashdividend validation. Conclusion: no PROPOSE, EXIT, ADJUST or FUND. Actual size0; retain245.69cash. All statistical, fundamental, technical, simulation, consequence, strategy andbacktestwork recorded; lessons104-106 apply next run. Current country/newsjobs remain informational; no eligible dated catalyst or required action before04UTC, so no newmonitor/job. WatchlistFTS/RY/ALV.DE; TXNMonly future separately registeredmerger-risk research; WOLFexcludeduntilentitlementmapping. Do not retune inspectedwindows. Sources https://www.aqr.com/-/media/AQR/Documents/Insights/White-Papers/Understanding-Defensive-Equity.pdf ; https://www.txnmenergy.com/investors/acquisition.aspx ; https://runway.adityaperswal.workers.dev/data/stock-bars ; primaryissuerlinks inobservations3451-3457. Archive656parts acknowledged/latest500verified; remainingreadbacklimitedbyquerycap,notmissingwrites. Finished approximately21minutes within43planned/45hard, no spending pressure used tojustifyrisk.
cash245.69
US entries13155
US snapshots12685
foreign histories47
crypto pairs36
tests27
return-15.83
drawdown18.76
sample44
win rate29.55
proposed notional0
archive parts656
53,617-contract expansion: no executable, robust, affordable long-option mispricing